Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.41 |
| ▸ | SLC10A1 | Q14973 | 11/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | F11 | P03951 | 3/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.33 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17838294 | 0.91 | SLC10A1 (0.44) | GRM4SLC10A1ALDH1A1L3MBTL1F11 | |
| SCHEMBL17838260 | 0.91 | SLC10A1 (0.44) | GRM4SLC10A1ALDH1A1L3MBTL1F11 | |
| SCHEMBL21497983 | 0.83 | GRM4 (0.42) | GRM4SLC10A1ALDH1A1L3MBTL1F11 | |
| SCHEMBL19881915 | 0.82 | GRM4 (0.49) | GRM4SLC10A1ALDH1A1L3MBTL1KCNH2 | |
| SCHEMBL17838291 | 0.81 | SLC10A1 (0.42) | GRM4SLC10A1ARFSCN1 | |
| SCHEMBL20467193 | 0.81 | SLC10A1 (0.42) | GRM4SLC10A1ARFSCN1 | |
| SCHEMBL17838303 | 0.81 | GRM4 (0.40) | GRM4SLC10A1KCNH2ARFSCN1 | |
| SCHEMBL21427803 | 0.80 | GRM4 (0.41) | GRM4SLC10A1ALDH1A1L3MBTL1AR | |
| SCHEMBL30294232 | 0.80 | GRM4 (0.41) | GRM4SLC10A1ALDH1A1L3MBTL1AR | |
| SCHEMBL28902794 | 0.80 | GRM4 (0.41) | GRM4SLC10A1ALDH1A1L3MBTL1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10450270-B2 | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | JANSSEN SCIENCES IRELAND UC (IE) | 2019-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10450270-B2 | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | GRHPR, AGXT, GLS2 | GRM4 2037/4885SLC10A1 64/4885ALDH1A1 4103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.